Table 2.
Comparison of patients with favorable and unfavorable outcome and determinants of treatment failure in patients with Corynebacterium spp. orthopedic device-related infection (univariate analysis).
| Outcome | Univariate analysis | |||||
|---|---|---|---|---|---|---|
| ODI | Favorable | Failure | p-value | OR (IC95%) | p-value | |
| Demographics | ||||||
| Male gender | 25 (65.8%) | 12 (54.5%) | 13 (81.3%) | 0.165 | 3.611 (0.798; 16.347) | 0.096 |
| Age (median, 95%CI), years | 53.1 (44.1;69.0) | 52.2 (47.5;69.0) | 54.0 (41.6;69.0) | 0.679 | 0.991 (0.956; 1.027) | 0.615 |
| Comorbidities | ||||||
| BMI (median, 95%CI), kg/m2 | 25.4 (22.9;28.6) | 24.5 (22.5;26.0) | 28.0 (23.5;28.9) | 0.100 | 1.199 (0.969; 1.484) | 0.095 |
| ASA score (median, 95%CI) | 1 (1.0;2.0) | 1 (1.0;2.0) | 1.5 (1.0; 2.3) | 0.589 | 1.250 (0.605; 2.584) | 0.547 |
| CCI (median, 95%CI) | 0 (0.0;1.8) | 0 (0.0;1.0) | 0.5 (0.0;2.0) | 0.453 | 1.325 (0.809; 2.171) | 0.263 |
| BJI mechanism | ||||||
| Superinfection | 16 (42.1%) | 8 (36.4%) | 8 (50.0%) | 0.511 | 1.750 (0.472; 6.483) | 0.402 |
| Inoculation mechanism | 38 (100%) | 22 (100%) | 16 (100%) | |||
| Post-operative | 37 (97.4%) | 22 (100%) | 15 (93.8%) | 0.421 | NC | NC |
| Post-traumatic | 16 (42.1%) | 10 (45.5%) | 6 (37.5%) | 0.744 | 0.720 (0.193; 2.681) | 0.624 |
| BJI chronology | ||||||
| Early infection (< 3 months) | 25 (69.4%) | 13 (61.9%) | 12 (80.0%) | 0.295 | 2.462 (0.527; 11.500) | 0.252 |
| Chronic infection (>4 weeks) | 33 (86.8%) | 18 (81.8%) | 15 (93.8%) | 0.374 | 3.333 (0.336; 33.113) | 0.304 |
| Diagnostic features | ||||||
| Sinus tract | 21 (63.6%) | 13 (61.9%) | 8 (66.7%) | 1.000 | 1.231 (0.278; 5.454) | 0.785 |
| Abscess | 6 (18.8%) | 2 (10.0%) | 4 (33.3%) | 0.165 | 4.500 (0.679; 29.808) | 0.119 |
| Biological inflammatory syndrome | 26 (78.8%) | 14 (70.0%) | 12 (92.3%) | 0.202 | 5.143 (0.540; 48.943) | 0.154 |
| Initial plasmatic CRP level (mg/L) | 30.0 (15.0;93.9) | 20.0 (14.0;46.0) | 52.4 (20.1;96.2) | 0.414 | 0.999 (0.991; 1.007) | 0.824 |
| Surgical management | 36 (94.7%) | 22 (100%) | 14 (87.5%) | 0.171 | NC | NC |
| Inappropriate surgical strategy | 9 (25.0%) | 4 (18.2%) | 5 (35.7%) | 0.147 | 3.500 (0.808–15.163) | 0.094 |
| Surgical strategy | ||||||
| DAIR/debridement | 14 (38.9%) | 7 (31.8%) | 7 (50.0%) | 0.314 | 2.143 (0.539; 8.512) | 0.279 |
| One-stage exchange | 1 (2.8%) | 1 (4.5%) | 0 (0.0%) | 1.000 | NC | NC |
| Two-stage exchange | 11 (30.6%) | 9 (40.9%) | 2 (14.3%) | 0.142 | 0.241 (0.043; 1.346) | 0.105 |
| Definitive device ablation | 10 (27.8%) | 5 (22.7%) | 5 (37.5%) | 0.462 | 1.889 (0.430; 8.295) | 0.400 |
| Two-stage exchange OR definitive device ablation | 21 (58.3%) | 14 (63.6%) | 7 (50.0%) | 0.499 | 0.571 (0.147; 2.228) | 0.420 |
| Flap coverage requirement | 5 (13.2%) | 2 (9.1%) | 3 (18.8%) | 0.632 | 2.308 (0.338; 15.750) | 0.393 |
95%CI, 95% confidence interval; ASA, American society of anesthesiologists; BMI, Body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; NC, Not calculable; ODI, Orthopedic device-related infection; OR, Odd ratio; PJI, Prosthetic joint infection.